Literature DB >> 14766191

Influenza drift and epidemic size: the race between generating and escaping immunity.

Maciej F Boni1, Julia R Gog, Viggo Andreasen, Freddy B Christiansen.   

Abstract

Influenza in humans is characterised by strongly annual dynamics and antigenic evolution leading to partial escape from prior host immunity. The variability of new epidemic strains depends on the amount of virus currently circulating. In this paper, the amount of antigenic variation produced each year is dependent on the epidemic size. Our model reduces to a one-dimensional map and a full mathematical analysis is presented. This simple system suggests some basic principles which may be more generally applicable. In particular, for diseases with antigenic drift, vaccination may be doubly beneficial. Not only does it protect the population through classical herd immunity, but the overall case reduction reduces the chance of new variants being produced; hence, subsequent epidemics may be milder as a result of this positive feedback. Also, a disease with a high innate rate of antigenic variation will always be able to invade a susceptible population, whereas a disease with less potential for variation may require several introduction events to become endemic.

Entities:  

Mesh:

Year:  2004        PMID: 14766191     DOI: 10.1016/j.tpb.2003.10.002

Source DB:  PubMed          Journal:  Theor Popul Biol        ISSN: 0040-5809            Impact factor:   1.570


  28 in total

1.  Epidemic dynamics and antigenic evolution in a single season of influenza A.

Authors:  Maciej F Boni; Julia R Gog; Viggo Andreasen; Marcus W Feldman
Journal:  Proc Biol Sci       Date:  2006-06-07       Impact factor: 5.349

2.  The reinfection threshold regulates pathogen diversity: the case of influenza.

Authors:  Dinis Gökaydin; José B Oliveira-Martins; Isabel Gordo; M Gabriela M Gomes
Journal:  J R Soc Interface       Date:  2007-02-22       Impact factor: 4.118

3.  Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.

Authors:  Roberto Pradas-Velasco; Fernando Antoñanzas-Villar; María Puy Martínez-Zárate
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  The generation of influenza outbreaks by a network of host immune responses against a limited set of antigenic types.

Authors:  Mario Recker; Oliver G Pybus; Sean Nee; Sunetra Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

5.  Dynamic Perspectives on the Search for a Universal Influenza Vaccine.

Authors:  Chadi M Saad-Roy; Adrian B McDermott; Bryan T Grenfell
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

6.  The impact of seasonal and year-round transmission regimes on the evolution of influenza A virus.

Authors:  Ben Adams; Alice Carolyn McHardy
Journal:  Proc Biol Sci       Date:  2010-12-22       Impact factor: 5.349

7.  No coexistence for free: neutral null models for multistrain pathogens.

Authors:  Marc Lipsitch; Caroline Colijn; Ted Cohen; William P Hanage; Christophe Fraser
Journal:  Epidemics       Date:  2008-11-04       Impact factor: 4.396

8.  Rapid evolution of pandemic noroviruses of the GII.4 lineage.

Authors:  Rowena A Bull; John-Sebastian Eden; William D Rawlinson; Peter A White
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

9.  Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.

Authors:  Arun K Kashyap; John Steel; Adam Rubrum; Angeles Estelles; Raffaella Briante; Natalia A Ilyushina; Li Xu; Ryann E Swale; Aleksandr M Faynboym; Pamela K Foreman; Michael Horowitz; Lawrence Horowitz; Richard Webby; Peter Palese; Richard A Lerner; Ramesh R Bhatt
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

10.  Conjunction of factors triggering waves of seasonal influenza.

Authors:  Ishanu Chattopadhyay; Emre Kiciman; Joshua W Elliott; Jeffrey L Shaman; Andrey Rzhetsky
Journal:  Elife       Date:  2018-02-27       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.